Regulation of eosinophil function by phosphatidylinositol-specific PLC and cytosolic PLA(2)

Am J Physiol Lung Cell Mol Physiol. 2001 Oct;281(4):L844-51. doi: 10.1152/ajplung.2001.281.4.L844.

Abstract

We examined the regulatory role of cytosolic phospholipase A(2) (cPLA(2)) and phosphatidylinositol (PI)-specific phospholipase C (PLC) in the degranulation of human eosinophils and leukotriene (LT) C(4) synthesis. Activation with formyl-Met-Leu-Phe + cytochalasin B (fMLP/B) caused a time-dependent release of eosinophil peroxidase (EPO) and LTC(4), which was inhibited by pertussis toxin. By immunoblotting, eosinophil PLC-beta2 and -gamma2 isoforms were identified, and PLC activation was measured as a function of inositol 1,4,5-trisphosphate concentration. Stimulated release of EPO and intracellular Ca(2+) concentration was inhibited by ET-18-OCH(3), a PI-PLC inhibitor, whereas trifluoromethylketone (TFMK), a cPLA(2) blocker, had no inhibitory effect. Both TFMK and ET-18-OCH(3) attenuated stimulated arachidonate release and LTC(4) secretion, suggesting that activation of both PLC and cPLA(2) is essential for LTC(4) synthesis caused by fMLP/B. The structurally unrelated protein kinase C inhibitors bisindolylmaleimide, Ro-31-8220, and Go-6976 all blocked fMLP/B-induced EPO release but not LTC(4) secretion. 1,2-bis(2-Aminophenoxy)ethane-N,N,N',N'- tetraacetic acid acetoxymethyl ester, an intracellular Ca(2+) chelator, suppressed both EPO release and LTC(4) secretion. We found that fMLP/B-induced LTC(4) secretion from human eosinophils is regulated by PI-PLC through calcium-mediated activation of cPLA(2). However, cPLA(2) does not regulate eosinophil degranulation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Arachidonic Acid / metabolism
  • Biomarkers
  • Calcium / metabolism
  • Chelating Agents / pharmacology
  • Cytosol / enzymology
  • Egtazic Acid / analogs & derivatives
  • Egtazic Acid / pharmacology
  • Eosinophil Peroxidase
  • Eosinophils / drug effects
  • Eosinophils / enzymology*
  • Eosinophils / metabolism
  • Humans
  • Inositol 1,4,5-Trisphosphate / metabolism
  • Isoenzymes / metabolism
  • Ketones / pharmacology
  • Leukotriene C4 / biosynthesis
  • Leukotriene C4 / metabolism
  • Peroxidases / metabolism
  • Pertussis Toxin
  • Phosphatidylinositol Diacylglycerol-Lyase
  • Phosphodiesterase Inhibitors / pharmacology
  • Phosphoinositide Phospholipase C
  • Phospholipase C beta
  • Phospholipase C gamma
  • Phospholipases A / metabolism*
  • Phospholipid Ethers / pharmacology
  • Protein Kinase C / antagonists & inhibitors
  • Protein Kinase C / metabolism
  • Type C Phospholipases / metabolism*
  • Virulence Factors, Bordetella / pharmacology

Substances

  • Biomarkers
  • Chelating Agents
  • Isoenzymes
  • Ketones
  • Phosphodiesterase Inhibitors
  • Phospholipid Ethers
  • Virulence Factors, Bordetella
  • edelfosine
  • Arachidonic Acid
  • Leukotriene C4
  • Egtazic Acid
  • Inositol 1,4,5-Trisphosphate
  • Eosinophil Peroxidase
  • Peroxidases
  • Pertussis Toxin
  • Protein Kinase C
  • Phospholipases A
  • Type C Phospholipases
  • PLCB2 protein, human
  • Phosphoinositide Phospholipase C
  • Phospholipase C beta
  • Phospholipase C gamma
  • Phosphatidylinositol Diacylglycerol-Lyase
  • 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid
  • Calcium